Cargando…
Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study
AIMS: Type 2 diabetes mellitus (T2DM) is commonly complicated by renal impairment. Polyethylene glycol loxenatide (PEX168) is a novel long‐acting glucagon‐like peptide‐1 receptor agonist for T2DM. PEX168 pharmacokinetics was studied to identify requirements for dose‐modification in T2DM complicated...
Autores principales: | Wang, Jianwen, Huang, Jie, Li, Wei, Tang, Shiqi, Sun, Jian, Zhang, Xianming, Liu, Jun, Yi, Bin, Liu, Jishi, Zhang, Xingfei, Yang, Qian, Yang, Xiaoyan, Yang, Shuang, Yang, Guoping, Zhang, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955414/ https://www.ncbi.nlm.nih.gov/pubmed/31396983 http://dx.doi.org/10.1111/bcp.14091 |
Ejemplares similares
-
Polyethylene Glycol Loxenatide (PEX-168) Reduces Body Weight and Blood Glucose in Simple Obese Mice
por: Wu, Yuting, et al.
Publicado: (2021) -
Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice
por: Zhang, Yu, et al.
Publicado: (2021) -
Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
por: Liu, Lei, et al.
Publicado: (2022) -
Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota
por: Chen, Fengwu, et al.
Publicado: (2022) -
Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials
por: Salamah, Hazem Mohamed, et al.
Publicado: (2023)